Deals

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy
Astellas PharmaAudax Biosciences

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Pharma Inc. (TYO: 4503) and Audax Biosciences Pty Ltd jointly announced that the two parties have entered into an exclusive option and license agreement for DAX-044, Audax's lead oncology…

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
COVID-19CRO / CMO / CDMO

Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market

BiosimilarsCRO / CMO / CDMO

Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion

Biocytogen PharmaceuticalsCancer

Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO

CancerGenentech

Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech

Show More